WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaREGULATORY MATTERS
Ver el documentoACETYLSALICYLIC ACID - MHRA confirms labelling change
Ver el documentoACITRETIN - Warnings of depression added to label
Ver el documentoASTEMIZOLE - Withdrawn due to life-threatening ventricular arrhythmias
Ver el documentoCAMELIA SINENSIS - Ethanolic extract products withdrawn due to hepatotoxicity
Ver el documentoDIETARY SUPPLEMENTS - Withdrawal of two products due to presence of sildenafil
Ver el documentoHUA FO - Presence of tadalafil
Ver el documentoIODINE - Some products contain more than the RDA
Ver el documentoLEVODOPA/CARBIDOPA - New warning about somnolence and sudden onset sleep
Ver el documentoLINDANE - Additional warnings and medication guide added to label
Ver el documentoNEFAZODONE - Regulatory status update
Ver el documentoNIMESULIDE - Paediatric preparations banned in Bangladesh
Ver el documentoPERGOLIDE MESYLATE - Risk of cardiac valvulopathy
Ver el documentoREPAGLINIDE - Contraindicated with gemfibrozil
Ver el documentoRISPERIDONE - Prescribing information updated to reflect cardiovascular adverse events
Ver el documentoTELITHROMYCIN - Aggravation of myasthenia gravis
Abrir esta carpeta y ver su contenidoSAFETY OF MEDICINES
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE

IODINE - Some products contain more than the RDA

Canada. Health Canada is advising consumers against using some products containing iodine (SEAVITE Premium Atlantic Kelp Blend and SEAVITE Premium Atlantic Kelp tablets) since these products, when consumed according to the label instructions, can provide 25 times the recommended daily allowance (RDA) of iodine for adults; this could lead to serious adverse health consequences. The RDA for iodine ranges from 90 micrograms per day for children aged 1-8 years to 150 micrograms per day for adults. Excessive iodine intake could lead to thyroid disorders and in turn to heart problems. Three reports of serious adverse events have been associated with the use of these products; one patient required hospitalisation. The excessive iodine can manifest itself as an under- or over-active thyroid. Individuals especially sensitive to the toxic effect of excess iodine include children of all ages, pregnant women, foetuses and newborns of breast feeding women and those under previous or current supervision for thyroid disease. Individuals taking amiodarone, a prescription drug for treating heart rhythm disorders may also be at increased risk. Health Canada warns that concerned consumers should talk to their healthcare provider.

Health Canada Warnings/Advisories, 8 May 2003. Available from URL: http://www.hc-sc-gc.ca

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019